| Literature DB >> 22134399 |
Mariele Caroline Marques Nogueira Puhl1, Diógenes Aparício Garcia Cortez, Tânia Ueda-Nakamura, Celso Vataru Nakamura, Benedito Prado Dias Filho.
Abstract
One of the oldest forms of medical practice is the use of plants for the treatment and prevention of diseases that affect humans. We have studied the antimicrobial activity and synergism of Piper gaudichaudianum Kuntze with different antibiotics. The crude extract from the leaves of P. gaudichaudianum was submitted to chromatographic separation, resulting in five fractions. Fraction F3 contained a chromone (2,2-dimethyl-6-carboxycroman-4-one), and fraction F2 contained isomers that are prenylated derivatives of benzoic acid [4-hydroxy-(3',7'-dimethyl-1'-oxo-octa-E-2'-6'-dienyl)benzoic acid and 4-hydroxy-(3',7'-dimethyl-1'-oxo-octa-2'-Z-6'-dienyl) benzoic acid]. The chemical structures of both compounds were determined by analysis of ¹H-NMR, ¹³C-NMR, COZY, DEPT, HMQC, and HMBC spectral data, and by comparison with data in the literature. The crude extract, fraction F2, and fraction F3 showed good activity against Staphylococcus aureus, Bacillus subtilis, and Candida tropicalis. The two benzoic acid derivatives only showed activity against S. aureus and B. subtilis. The bioauthographic analysis showed an inhibition zone only in fraction F2. Fractions F2 and F3 showed synergism in combination with ceftriaxone, tetracycline, and vancomycin. Morphological changes in form and structure were found by scanning electron microscopy in S. aureus treated with the combination of fraction F2 with vancomycin.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22134399 PMCID: PMC6264199 DOI: 10.3390/molecules16129925
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 12,2-dimethyl-6-carboxycroman-4-one.
Figure 2Structures of prenylated benzoic acid derivatives 2 and 3.
Figure 3Bioautographic crude extracts and fractions isolated from the leaves of P. gaudichaudianum. The plate A was used for bioautography with S. aureus and the plate B was revealed with reactive Godin. Arrows indicate zones of inhibition of the fraction F2 and the band corresponding to the chromatographic plate. The reference compound on the plate was amikacin (C).
Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and minimum fungicidal concentration (MFC) of aqueous and crude extracts obtained from the leaves of P. gaudichaudianum and antibiotics used.
| Samples/ Antibiotics | Antimicrobial Activity (µg/mL) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |||||||||
| MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MFC | MIC | MFC | MIC | MFC | MIC | MFC | |
| AE | >1000 | - | >1000 | - | >1000 | - | >1000 | - | >1000 | - | >1000 | - | >1000 | - | >1000 | - |
| CE | 250 | 500 | 62.5 | 62.5 | >1000 | - | >1000 | - | >1000 | - | 62.5 | 125 | >1000 | - | 1000 | - |
| Ceftriaxone | 6,25 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Chloraphenicol | 12,5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Penicillin | 0,02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Tetracycline | 0,39 | - | - | - | 1 | - | 12,5 | - | - | - | - | - | - | - | - | - |
| Vancomycin | 1,25 | - | 0,2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Fluconazole | - | - | - | - | - | - | - | - | 7,8 | - | >250 | - | 1,9 | - | 1,56 | - |
(−) unspecified.
Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and minimum fungicidal concentration (MFC) of fractions and pure compounds obtained from the leaves of P. gaudichaudianum.
| Samples / Antibiotics | Antimicrobial Activity (µg/mL) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |||||||||
| MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MFC | MIC | MFC | MIC | MFC | MIC | MFC | |
| F1 | 1000 | - | 1000 | - | >1000 | - | >1000 | - | >1000 | - | 62.5 | 125 | >1000 | - | 500 | - |
| F2 | 62,5 | 62,5 | 15,6 | 15,6 | >1000 | - | >1000 | - | >1000 | - | 62.5 | 125 | >1000 | - | 250 | - |
| F3 | 125 | >1000 | 31.2 | 31.2 | >1000 | - | >1000 | - | >1000 | - | 250 | 500 | >1000 | - | 500 | - |
| F4 | >1000 | - | >1000 | - | >1000 | - | >1000 | - | >1000 | - | 500 | 500 | >1000 | - | 1000 | - |
| F5 | >1000 | - | >1000 | - | >1000 | - | >1000 | - | >1000 | - | 1000 | >1000 | >1000 | - | 1000 | - |
| FDA 47-58 | 31,25 | 62,5 | 7,81 | 7,81 | >1000 | - | >1000 | - | >1000 | 1000 | - | >1000 | - | - | - | |
| FDB 9 | 12,5 | 12,5 | 6,25 | 6,25 | >1000 | - | >1000 | - | >1000 | - | >1000 | - | >1000 | - | - | - |
(−) unspecified.
Figure 4(A) Isobologram representing synergy between ceftriaxone and F3 against S. aureus; (B) Isobologram representing synergism between vancomycin and F2 against S. aureus; (C) Isobologram representing synergism between tetracycline and F3 against S. aureus; The dashed line indicates the theoretical additive activity.
Figure 5Scanning electron microscopy. (A) S. aureus without treatment (control); (B) S. aureus treated with fraction F2 (50 mg/mL); (C and D) S. aureus treated with vancomycin (0.63 μg/mL). (E and F) S. aureus treated with combinations of fraction F2 (6.25 μg/mL) and vancomycin (0.63 μg/mL).